Regeneron Pharmaceuticals (REGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of five directors: Joseph L. Goldstein, Christine A. Poon, David P. Schenkein, Craig B. Thompson, and Huda Y. Zoghbi, with board recommending a vote for each.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Advisory vote to approve compensation of Named Executive Officers, with board recommending approval.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election at the 2026 Annual Meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with board recommending approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Regeneron Pharmaceuticals
- Board declassification, strong R&D, and robust ESG drive growth and shareholder alignment.REGN
Proxy filing24 Apr 2026 - Cemdisiran ± pozelimab delivers strong late-stage efficacy and safety, targeting major growth markets.REGN
Status update22 Apr 2026 - Robust pipeline, strong brand growth, and major 2026 milestones drive future outlook.REGN
44th Annual J.P. Morgan Healthcare Conference21 Apr 2026 - EYLEA HD and DUPIXENT drive growth as pipeline and strategic initiatives expand into new areas.REGN
Leerink Global Healthcare Conference 202611 Mar 2026 - Dupixent and EYLEA HD fuel growth as pivotal pipeline readouts approach in 2024–2025.REGN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong earnings growth, pipeline innovation, and disciplined capital allocation drive future value.REGN
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - All voting items passed, with robust financials and major pipeline advances highlighted.REGN
AGM 20243 Feb 2026 - Q2 revenue up 12% to $3.55B, led by Dupixent, EYLEA HD, and Libtayo; net income up 48%.REGN
Q2 20242 Feb 2026 - Q4 2025 revenue up 3% YoY, driven by Dupixent and EYLEA HD growth, with major approvals.REGN
Q4 20252 Feb 2026